残余胆固醇在脑小血管病中的研究进展

燚辉 侯(承德医学院附属医院，中国)
志杰 窦(承德医学院附属医院，中国)

摘要

脑小血管病起病隐匿，可表现为腔隙性脑梗死、认知障碍、运动障碍等，可导致神经功能丧失及认知障碍等。残余胆固醇是所有富含甘油三酯脂蛋白的胆固醇的含量，可以通过损伤内皮细胞、促进炎症和血栓形成等机制直接促进动脉粥样硬化的发展，目前的治疗方案主要为调整生活方式、使用降脂类药物等。本文主要探讨残余胆固醇与脑小血管病的关系、残余胆固醇的定义及评估方法、代谢途径、致病机制及影响因素等进行描述，以期为临床控制残余胆固醇提供借鉴。

关键词

残余胆固醇；脑小血管病；治疗；致病机制

参考

中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组.中国脑小血管病诊治指南2020[J].中华神经科杂志,2022,55(8):807-818.

胡文立,杨磊,李譞婷,等.中国脑小血管病诊治专家共识2021[J].中国卒中杂志,2021,16(7):716-726.

Ren B, Tan L, Song Y, et al. Cerebral Small Vessel Disease:Neuroimaging Features, Biochemical Markers, Influencing Factors,Pathological Mechanism and Treatment[J]. Front Neurol, 2022(13):843953.

Cannistraro R J, Badi M, Eidelman BH, et al. small vessel disease: a clinical review[J]. Neurology, 2019(92):1146–1156.

Amarenco P, Kim J S, Labreuche J, et al. Treat Stroke to Target Investigators. A comparison of two ldl cholesterol targets after ischemic stroke[J]. N Engl J Med, 2020,382(1): 9.

Varbo A, Nordestgaard B G. Remnant cholesterol and risk of ischemic stroke in 112,512 individuals from the general population[J]. Ann Neurol, 2019,85(4):550-559.

Wadström B N, Wulff A B, Pedersen KM, et al. Elevated remnant cholesterol increases the risk of peripheral artery disease, myocardial infarction, and ischaemic stroke: a cohort-based study[J]. Eur Heart J, 2022,43(34):3258-3269.

Yang X H, Zhang B L, Cheng Y, et al. Association of remnant cholesterol with risk of cardiovascular disease events, stroke, and mortality: A systemic review and meta-analysis[J]. Atherosclerosis, 2023,371:21-31.

Di Costanzo A, Perla F M, D’Erasmo L, et al. Elevated Serum Concentrations of Remnant Cholesterol Associate with Increased Carotid Intima-Media Thickness in Children and Adolescents[J]. Pediatr, 2021,232:133-139.e1.

Liu B, Fan F, Zheng B, et al. Association of remnant cholesterol and lipid parameters with new-onset carotid plaque in Chinese population[J]. Front Cardiovasc Med, 2022(9):903390.

Varbo A, Benn M, Tybjærg-Hansen A, et al. Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation[J]. Circulation, 2013,128(12):1298-309.

Wang Z, Li M, Xie J, et al. Association between remnant cholesterol and arterial stiffness: A secondary analysis based on a cross-sectional study[J]. Clin Hypertens, Greenwich, 2022,24(1):26-37.

Sandesara P B, Virani S S, Fazio S, et al. The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk[J]. Endocr Rev, 2019,40(2):537-557.

黄本林,王宁,王妮,等.估算法和测量法在血清残余脂蛋白胆固醇评估中的比较[J].临床检验杂志,2022,40(4):257-261.

Martin S S, Blaha M J, Elshazly M B, et al. Friedewald-estimated versus directly measured low-density lipoprotein cholesterol and treatment implications[J]. Am Coll Cardiol, 2013(62):732

Gugliucci A. Triglyceride-Rich Lipoprotein Metabolism: Key Regulators of Their Flux[J]. Clin Med, 2023,12(13):4399.

Chin J, Mori T A, Adams L A, et al. Association between remnant lipoprotein cholesterol levels and non-alcoholic fatty liver disease in adolescents[J].HEP Rep, 2020,2(6):100150.

Hoogeveen R C, Ballantyne C M. Residual Cardiovascular Risk at Low LDL: Remnants, Lipoprotein(a), and Inflammation[J]. Clin Chem, 2021,67(1):143-153.

Feingold K R. Lipid and Lipoprotein Metabolism[J]. Endocrinol Metab Clin North Am, 2022,51(3):437-458.

Center M, Francisco S. Introduction To Lipids and Lipoproteins[J].[2024-04-01].

Kersten S. Physiological regulation of lipoprotein lipase[J]. Biochim Biophys Acta, 2014,1841(7):919-933.

Varbo A, Nordestgaard B G. Remnant lipoproteins[J]. Curr Opin Lipidol, 2017,28(4):300-307.

Nordestgaard, Børge, G, et al. Triglycerides and cardiovascular disease[J].Lancet, 2014.

Nordestgaard B G, Langlois M R, Langsted A, et al. Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM[J]. Atherosclerosis, 2020:294.

Taskinen M R, Björnson E, Packard C J. Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia[J]. Nat Rev Cardiol, 2022,19(9):577-592.

Masuda D, Yamashita S. Postprandial Hyperlipidemia and Remnant Lipoproteins[J]. Atheroscler Thromb, 2017,24(2):95-109.

Chen X, Li L H. Remnant Cholesterol, a Valuable Biomarker for Assessing Arteriosclerosis and Cardiovascular Risk: A Systematic Review[J]. Cureus, 2023,15(8):e44202.

Wang L, Gill R, Pedersen T L, et al. Triglyceride-rich lipoprotein lipolysis releases neutral and oxidized FFAs that induce endothelial cell inflammation[J]. Lipid Res, 2009,50(2):204-213.

Lin A, Nerlekar N, Rajagopalan A, et al. Remnant cholesterol and coronary atherosclerotic plaque burden assessed by computed tomography coronary angiography[J]. Atherosclerosis, 2019.

赵鑫,蒋欣,崔佩,等.残余胆固醇与缺血性卒中[J].国际脑血管病杂志,2022,30(4):280-284.

Gabani M, Shapiro M D, Toth P P. The Role of Triglyceride-rich Lipoproteins and Their Remnants in Atherosclerotic Cardiovascular Disease[J]. Eur Cardiol, 2023(18):e56.

Visseren F L J, Mach F, Smulders Y M, et al. ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice[J]. Eur J Prev Cardiol, 2022,29(1):5-115.

Tsunoda F, Asztalos I B, Horvath K V, et al. Fenofibrate, HDL, and cardiovascular disease in Type-2 diabetes: the DAIS trial[J]. Atherosclerosis, 2016(247):35-39.

Wang K, Wang R, Yang J, et al. Remnant cholesterol and atherosclerotic cardiovascular disease: Metabolism, mechanism, evidence, and treatment[J]. Front Cardiovasc Med, 2022(9):913869.

Arai H, Yamashita S, Yokote K, et al. a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia[J]. Atherosclerosis, 2017(261):144-152.

Musunuru K, Kathiresan S. Surprises From Genetic Analyses of Lipid Risk Factors for Atherosclerosis[J]. Circ Res, 2016,118(4):579-585.

Tall A R, Thomas D G, Gonzalez-Cabodevilla A G, et al. Addressing dyslipidemic risk beyond LDL-cholesterol[J]. Clin Invest, 2022,132(1):e148559.

Heo J H, Jo S H. Triglyceride-Rich Lipoproteins and Remnant Cholesterol in Cardiovascular Disease[J]. Korean Med Sci, 2023,38(38):e295.

Rosenson R S, Shaik A, Song W. New Therapies for Lowering Triglyceride-Rich Lipoproteins: JACC Focus Seminar 3/4[J]. Am Coll Cardiol, 2021,78(18):1817-1830.

Pintó X, Fanlo M, Esteve V, et al. Remnant cholesterol, vascular risk, and prevention of atherosclerosis[J]. Clin Investig Arterioscler, 2023,35(4):206-217.

DOI: http://dx.doi.org/10.12345/yzlcyxzz.v7i4.17084